[Focusing on occupational safety in hyperthermic intraperitoneal chemotherapy: a systematic review]

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) serves as a core treatment modality for malignant tumors on the peritoneal surface, with its clinical application growing increasingly widespread. However, the potential genotoxicity, teratogenicity, and carcinogenicity of chemotherapy drugs expose healthcare workers to occupational risks. This review systematically analyzes 10 relevant research papers, organizing existing evidence on HIPEC occupational safety around five core variables: collective protective equipment, personal protective equipment, air sample monitoring, surface sampling monitoring, and biological sample monitoring. Results indicate that overall occupational exposure risks during HIPEC are relatively low. Chemotherapy drugs were mostly undetectable or below detection limits in air samples. Surface contamination, such as the outer surface of gloves, the floor in surgical areas, and equipment reservoirs,represents primary risk points. Protective measures including double- or triple-layer gloves and fume extraction systems can effectively reduce exposure risks. Biological sample monitoring indicates that chemotherapy drug markers were not detected in the urine or plasma of most healthcare workers. However, a few studies have identified irinotecan and its active metabolites in red blood cells.